InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
